Exercise training (ET) in heart failure (HF) has long been established as an important part of HF care. ET is known to improve quality of life and functional capacity in a number of ways. Despite its proposed benefits, evidence supporting its routine inclusion in standard rehabilitation programme is at times conflicting, partly because of the significant heterogeneity present in available randomised controlled trials. There is lack of evidence with regard to the duration of the overall benefit, the optimal exercise regimen and whether certain types of HF aetiologies benefit more than others. The aim of this review is to provide an update to date literature review of the positive and negative evidence surrounding ET in HF, while proposing an efficient novel in-hospital exercisebased rehabilitation programme for patients with HF in addition to a pre-existing HF clinic.
Heart failure (HF) is a frequently distressing condition, affecting 1%-2% of the adult population in developed countries. [1] [2] [3] [4] Better management of patients with HF has led to higher costs, putting pressure on healthcare providers to support patient care. The poor quality of life (QOL) as a result of high symptom burden, 5 6 along with a vast range of interplaying factors has opened the door for a more comprehensive approach which helps to facilitate health behaviour modification and self-management by lifestyle risk factor management. 7 Structured and physician supervised multidisciplinary cardiac rehabilitation (CR) programmes have been shown to improve symptoms and functional capacity, together with an overall reduction in HF-specific and overall hospitalisation rates. 8 
Concepts of Cr
Back in the 1950s, bed rest and eventually armchair treatment were widespread cardiology practice in patients presenting with heart disease. Early mobilisation in the 1970s transformed cardiology, as healthcare providers realised that cardiac and skeletal muscle deconditioning compromised patients' rehabilitation. Risk stratification of patients presenting with acute coronary syndrome in the 1980s allowed physicians to better advise gradual resumption of daily activities. The latter's importance eventually paved the way for CR programmes.
At present, rehabilitation programmes are delivered in hospital-based outpatient clinics or in community centres, depending on the healthcare system, usually starting 2-4 weeks after a cardiac event or 4-6 weeks after cardiac surgery. Delivered by specialised CR nurses, physiotherapists and exercise therapists, such a service is only possibly through an integrated multidisciplinary team, led by an experienced CR clinician. 9 Following clinical assessment, six core components (box 1) help define how and what material should be included in a holistic CR programme, as per the latest British Association for Cardiovascular Prevention and Rehabilitation standard recommendations. 10 Such measures help ensure the delivery of high-quality content. Patients are required to attend a number of group-based sessions, often two to three times a week for 4-6 weeks. This would consist of medical evaluation, prescribed exercise, cardiac risk factor modification, education and counselling (box 2).
11 Early identification and treatment of coexisting diseases such as obstructive sleep apnoea, peripheral artery disease and psychiatric disorders have also been shown to improve QOL in this high-risk population [12] [13] [14] which is why screening for these conditions is also incorporated in some programmes. Empowering patients and ensuring optimal medical therapy will increase the likelihood of patients adhering to advice and lifestyle modifications.
Exercise training: the weak link
Comprehensive exercise-based CR programmes lead to significant improvements in a number of clinically relevant end points. [14] [15] [16] HF clinics around the world have had a pivotal role in ensuring that the core components of CR in HF are met. 17 In this regard, a lot of emphasis is put on managing the traditional CV risk factors. Despite years of evidence backing early physical conditioning in HF, 18 HF clinics around the world still poorly implement exercise training (ET) in daily clinical practice. 19 Less than 20% of patients with HF were participating in a CR programme, 20 with analysis of another cohort revealing that only 42% of those attending an HF management programme had an exercise component.
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Evidence supporting ET in HF
The benefits of exercise have long been established in a number of small studies. Back in the days when medical treatment for HF was rather limited, Sullivan et al in 1988 18 had already demonstrated the benefits of exercise in these patients. Various reports have constantly shown improvements in functional capacity and QOL, persisting even beyond 12 months. 22 23 The 'Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training' (HF-AC-TION) study is the landmark multicentre randomised controlled trial (RCT) of ET in HF, consisting of 2331 patients, followed up for a median of 30 reveal any survival benefit for those attending ET programmes which could be partially explained by the young age of the cohort, lack of titration of the ET programme and poor compliance to their regimen. After adjusting for highly prognostic predictors of the primary endpoint, ET was associated with an 11% reduction (significant) in all-cause mortality/hospitalisation, together with a 15% reduction (significant) in cardiovascular mortality or HF hospitalisation. 24 25 Improved cardiorespiratory fitness (CRF) as illustrated by significant improvements in VO 2max , exercise duration on cardiopulmonary exercise testing and 6 min walking distance at 3 and 12 months were all demonstrated. 26 All these factors played an important role in a modest improvement in QOL. 25 27 Similar to a number of smaller RCTs, 28 HF-ACTION trial again confirmed that adverse events were not excessively higher in the ET group, removing any doubts that ET in HF does not only confer benefit, but is also safe. 26 A Cochrane review of exercise-based rehabilitation for HF (predominantly HF with reduced ejection fraction and New York Heart Association 2-3) in 4740 people (33 trials) again reaffirmed that ET reduced the rate of overall and HF-specific hospitalisation, together with an improvement in QOL, independent of the patient's age or degree of left ventricular (LV) dysfunction. These benefits were however only apparent after adjustment for highly prognostic predictors, independent of the mean dose of ET or length of follow-up. There was no survival advantage when comparing ET-based versus non-ET-based programmes. Two studies even reported that ET-based programmes could be potentially cost-effective, thanks to the quality of adjusted life years and life-years saved. 8 There is however limited data regarding the benefits of ET in the long term. 8 One study did however report a sustained improvement in functional capacity (>60% of VO 2Max ) and QOL, persisting up to 10 years, provided that supervised ET is performed regularly. These results together with the reported reduction in major cardiovascular events (HF-related hospitalisation and cardiac mortality) are encouraging. 29 
What about HF with preserved ejection fraction?
HF with preserved ejection fraction (HFPEF) is a fast growing form of HF, contributing towards 90% of newly diagnosed HF cases. 30 No medications have as yet been shown to positively influence primary endpoints, with only ET at present seemingly offering some hope, based on early datasets. 24 31 ET in HFPEF may help improve intrinsic oxygen utilisation in skeletal muscles 25 and augmented diastolic filling properties. 32 With only eight highly heterogeneous RCTs (278 patients) currently reported, [33] [34] [35] [36] [37] [38] [39] [40] it is difficult to make any solid conclusions. 31 One can however conclude that ET can be implemented safely in these patients, with some improvement in functional capacity and QOL to be expected. There is limited data on exercise-induced reversed cardiac remodelling and biomarkers. Knowledge about major clinical outcomes like hospitalisation and mortality is as yet unknown. 31 As HFPEF is often associated with many comorbid conditions which are anyway likely to benefit from ET, it would be reasonable to say that as things stand, there is no evidence which precludes physicians from encouraging this therapy to such patients. 24 
non-ischaemic HF: the wild card
The risk of sudden cardiac death in patients with non-ischaemic HF has hindered any developments with respect to ET. A number of small RCTs do claim ET offers significant benefit in non-ischaemic dilated cardiomyopathy. Improved exercise capacity, 41 LV remodelling, 41 VO 2Peak , 42 43 diastolic parameters 42 43 and endothelial function 44 have all been reported. Two small studies reported improved functional class 44 and exercise capacity (VO 2Mean ) 45 in patients with hypertrophic cardiomyopathy. Data from the ExTraMATCH meta-analysis did not show any evidence supporting ET in patients with non-ischaemic HF. 46 In conclusion, there is as yet not enough evidence to support structured ET in these patients.
selecting the optimal training protocol
There is no one universal protocol for ET in HF. An individualised approach should be pursued, after careful clinical and risk evaluation, taking into account a patient's lifestyle, personal goals and preferences. 18 The frequency, intensity, type and time principle (table 1) is used to help guide exercise prescription, delivered in a hospital or home-based setting in a supervised or unsupervised manner.
Various parameters from a symptom-limited cardiopulmonary exercise test are used to help set target goals to achieve better CRF in a safe manner. VO 2Max is one such variable, a very strong predictor of disease prognosis in HF, decreasing the risk of death by 15% with an increase of 1.0 mL/kg -1 min -1 . 47 Improved review achieved metabolic equivalents (METS) also offers prognostic benefit, with an increase of one MET achieved during a 12-week rehabilitation programme associated with a 13% reduction in overall mortality. 48 VO 2Max and METS are the two main parameters, used in prescribing training intensity during endurance exercise, with the heart rate recovery and Borg Rating of Perceived Exertion scale other good objective alternatives. 13 Less vigorous activities should be formulated for more deconditioned patients.
Moderate continuous intensity ET is the mainstay form of ET in HF. Its efficacy and safety are well demonstrated, highly recommended in guidelines. 18 With the advent of high-intensity interval training (HIIT) emerging over the past couple of years, studies show it is also effective, 49 well tolerated and safe for most patients with HF, improving functional capacity and QOL. 22 One single-centre study actually reported HIIT to be superior to moderate continuous intensity training (MCT) in enhancing VO 2Max by reversing LV remodelling, improving cardiac output and endothelial function, 50 with similar results reproduced separately. 51 These conclusions have however been rebuffed ever since results were not reproduced in a larger multicentre trial, the SMARTEX-HF trial, which did not show superiority of HIIT over MCT. 52 Resistance training adds muscle bulk to peripheral muscles and also increases bone mass. Augmenting blood flow to skeletal muscles decreases peripheral resistance and improves cardiac output. Despite its proposed benefits, it should complement and not substitute endurance exercise. 18 Respiratory training is another avenue which is as yet poorly explored. Exercise capacity and QOL improve when inspiratory muscle training is performed in those presenting with weakness of these muscles 53 which is why screening and specific training exercises should be considered in addition to endurance training.
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ExErCIsE CAPACITy In HF And undErlInG PHysIoloGICAl mECHAnIsms Pathways contributing towards impaired exercise capacity
A reduction in stroke volume coupled with lower heart rate reserve results in a number of changes in various body systems to try and compensate for poor cardiac output. 4 54 Central circulatory response During exercise, this is often manifested with shorter ventricular filling in response to physiological tachycardia. The ineffective increase in stroke volume in patients with systolic dysfunction and the inability to increase chamber distensibility in patients with diastolic dysfunction are the two main mechanisms contributing towards diminished exercise capacity in patients with HF, 54 with the absence of other markers ruling out any pulmonary limitations.
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Peripheral response
In an attempt to maintain adequate cardiac output, peripheral hypoperfusion encourages skeletal muscle dysfunction and atrophy, consequently decreasing peripheral resistance. By diverting blood away from peripheral muscle groups, diverting blood towards the inspiratory muscles helps improve cardiac output efficiency, 58 a physiological response known as the metaboreflex. Augmented peripheral anaerobic metabolism during exercise promotes the release of lactic acid, 54 reduced enzymes for oxidative metabolism, 59 reductions in microvascular density 60 and decreased thigh cross-sectional area, 61 all of which correspond to a lower VO 2Max and total exercise time. 54 Endothelial dysfunction and activation of the sympathetic and renin-angiotensin aldosterone systems These all play a role in modulating vascular tone in patients with HF. 54 By upsetting the balance between nitric oxide, mechanotransducer stimulation and reactive oxygen species production, 62 63 vasoconstriction contributes towards ischaemic conditioning of skeletal muscles. These changes together with exercise-induced catecholamine release 64 favour anaerobic glycolysis, thereby promoting symptoms of exercise intolerance.
Physiological impact of ET
Improvements in clinically relevant primary endpoints and QOL as a result of ET are brought about by a number of adaptations which take place in a number of different systems.
Central adaptations
Training-induced reverse remodelling 18 65 66 with improved CRF 67 and NT-pro Brain Natriuretic Peptide (NT-proBNP) reductions have all been reported with ET. 68 The Exercise training in Diastolic Heart Failure pilot study 33 has also provided some insight into improved diastolic function in patients with HFPEF following ET, with further data expected in the follow-up study. 69 
Peripheral adaptations
Vasomotor dysregulation in peripheral muscles is also reversed at the cellular level with ET. 54 70-72 A correlation between VO 2Max and augmented peripheral blood flow provides strong evidence which suggests that peripheral adaptations improve CRF. 73 
Neurohormonal adaptations
Acetylcholine-mediated vasodilation and upregulation of antioxidative radical scavenger enzymes contributes towards improved peripheral vasomotor tone. [73] [74] [75] ET also encourages lower sympathetic nerve activity, thereby improved vagal tone and decreased sympathetic tone. [76] [77] [78] [79] These have been shown to decrease heart rate variability, leg vascular resistance, diastolic pressure and ventilation. 79 
Altered inflammatory status
Reduced inflammatory cytokine levels which correlate with improvements in VO 2Max have been reported, 80 suggesting that skeletal muscle myopathy in HF is partly inflammatory in aetiology. It has been a long and arduous struggle, taking 20 years for ET in stable HF to finally being accepted as a class 1 recommendation in international guidelines. 81 82 A number of healthcare or patient-related barriers hinder the implementation of ET in all HF clinics around the world. 19 82 It is well known that failing to advise patients regarding the importance of non-pharmacological treatment like exercise is a predictor of poor outcome in HF which is why practical interventions should be sought to help bridge the gap. 83 Lack of knowledge about the evidence supporting current recommendations, together with the limited availability of ET sites, insufficient financial investment and organisation-related factors are all valid healthcare system obstacles. 19 The physiology and benefit of exercise in general are not well addressed during medical and postgraduate training which is why courses and up-to-date lectures should be incorporated regularly.
review main messages
► Evidence supporting exercise training in heart failure is now well established, with small studies also showing positive benefits for heart failure with preserved ejection fraction and non-ischaemic cardiomyopathy. ► Exercise training alters multiple physiological mechanisms which help improve cardiac output and functional capacity, thereby reduce symptoms, improve quality of life and also help decrease hospitalisation. ► Despite the benefits of exercise training in heart failure dating back to the 70s, a number of factors are still hindering its widespread implementation in heart failure rehabilitation programmes.
Current research questions
► What is the current evidence supporting the widespread implementation of exercise training in patients with heart failure? ► Why does exercise training improve functional capacity in patients with heart failure? ► What is the status on exercise training prescription in heart failure with preserved ejection fraction and non-ischaemic heart failure? Patient adherence on the other hand is determined by the interaction of five different aspects, including social and economic factors, patient's condition, therapy, patient perception and factors related to the healthcare setting. 19 Demographic variables like age (younger than 65 years) and ethnicity (non-white patients) were significantly associated with worse adherence to CR in one meta-analysis. 84 Adherence to ET was specifically shown to be rather poor (<50%) in older patients, females and those with psychiatric issues. Lack of motivation, financial/ medical concerns and lower socioeconomic class were all shown to be strong predictors of poor adherence in one study. 85 Poor social support and barriers to exercise were associated with lower exercise time in the HF-ACTION trial. 10 86 This same trial also reported that lack of enthusiasm and patient symptoms were the main reasons for poor adherence with prescribed ET, with only 29%-42% managing to comply with prescribed regimens 3 months after completing the CR programme.
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ConClusIons
One can confidently conclude that ET in HF is safe, with the added possibility that it may reduce mortality and HF-related hospitalisation. The extensive study heterogeneity, along with the small sample sizes used for most RCTs makes it very difficult to arrive at solid conclusions. Larger studies are needed to assess the efficacy of ET in HF, while also looking at novel ways to improve adherence in exercise programmes.
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